NASDAQ · XLO
Healthcare · Biotechnology
$7.31
Down-$0.26 (-3.43%)
Updated Oct 27, 2026, 9:47 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · XLO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
XLO closed at $7.31 after 21 trading sessions, down 19.23% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $7.54 | $8.6368 | $7.05 | $7.31 | 33.45K |
| Oct 23, 2026 | $8.06 | $8.245 | $7.51 | $7.57 | 16.25K |
| Oct 22, 2026 | $8.45 | $8.48 | $8.00 | $8.03 | 15.37K |
| Oct 21, 2026 | $8.545 | $9.05 | $8.2487 | $8.43 | 36.27K |
| Oct 20, 2026 | $8.25 | $8.84 | $8.25 | $8.54 | 13.51K |
| Oct 19, 2026 | $8.69 | $8.735 | $8.33 | $8.33 | 11.49K |
| Oct 16, 2026 | $8.91 | $9.00 | $8.55 | $8.55 | 29.6K |
| Oct 15, 2026 | $8.88 | $9.38 | $8.88 | $9.02 | 10.39K |
| Oct 14, 2026 | $9.08 | $9.08 | $8.772 | $8.90 | 12.42K |
| Oct 13, 2026 | $9.05 | $9.22 | $8.855 | $9.22 | 18.15K |
| Oct 12, 2026 | $9.11 | $9.42 | $8.9815 | $9.075 | 8.39K |
| Oct 9, 2026 | $8.94 | $9.16 | $8.82 | $9.05 | 5.53K |
| Oct 8, 2026 | $9.01 | $9.14 | $8.775 | $9.01 | 20.79K |
| Oct 7, 2026 | $9.00 | $9.01 | $9.00 | $9.01 | 885.71 |
| Oct 6, 2026 | $9.10 | $9.32 | $8.81 | $9.00 | 6.2K |
| Oct 5, 2026 | $9.07 | $9.49 | $9.07 | $9.11 | 7.16K |
| Oct 2, 2026 | $8.89 | $9.075 | $8.89 | $9.01 | 7.4K |
| Oct 1, 2026 | $8.97 | $9.12 | $8.79 | $8.91 | 12.89K |
| Sep 30, 2026 | $9.19 | $9.25 | $9.05 | $9.05 | 5.38K |
| Sep 29, 2026 | $9.5677 | $9.5677 | $8.9378 | $8.9378 | 3.11K |
| Sep 28, 2026 | $9.21 | $9.22 | $8.96 | $9.05 | 11.13K |
The latest Smart Investors Daily articles mentioning XLO.
Company
Market Activity
Research & News
XLO research
Company profile and research snapshot.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 21, 2026 | Raymond James | Outperform | — |
| Aug 6, 2025 | Leerink Partners | Outperform | — |
| Nov 8, 2024 | Raymond James | Outperform | — |
| May 30, 2023 | Chardan Capital | Buy | — |
| May 11, 2023 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 21, 2026
Raymond James analyst Sean McCutcheon initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Outperform rating and announces Price Target of $16.
Yahoo · Oct 2, 2026
WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics’ Third Amended and Restated 2022 Inducement Stock Incentive Plan (the 2022
Yahoo · Sep 28, 2026
Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development, translational medicine and immuno-oncologyWALTHAM, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Dr. Yariv Houvras as chief medical officer. “We are thrill
Yahoo · Sep 2, 2026
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective September 1, 2026, the company granted non-qualified stock options to purchase 19,865 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $8.88
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning XLO.
